Graphite Bio is set to merge with LENZ Therapeutics through a reverse merger, via an all-stock transaction. The merged company will continue to operate under the name LENZ Therapeutics and trade on the Nasdaq under the ticker symbol “LENZ”. The merged entity will focus on advancing LENZ’s pipeline candidates intended to address presbyopia, with an estimated US market opportunity exceeding $3bn. The transaction is expected to close in Q1 2024.
Everything we know about the Hasbro hack so far
The toy-maker keeps running thanks to business continuity plans, but nature of attack remains unclear
